Tag #Drug Development

Showing 13 to 24 of 27 results

forbes.com

🌐 85% Global Worthiness

Mar 12, 19:14

Congress Weighs Reauthorization of Life-Saving Pediatric Drug Incentive Program

Congress can reauthorize the expired Pediatric Priority Review Voucher (PPRV) program to incentivize pharmaceutical companies to develop treatments for rare pediatric diseases without taxpayer costs; the program has already facilitated the approval of 50 life-saving treatments for 40 diseases.

Congress Weighs Reauthorization of Life-Saving Pediatric Drug Incentive Program

Congress can reauthorize the expired Pediatric Priority Review Voucher (PPRV) program to incentivize pharmaceutical companies to develop treatments for rare pediatric diseases without taxpayer costs; the program has already facilitated the approval of 50 life-saving treatments for 40 diseases.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of not reauthorizing the Pediatric Priority Review Voucher program?

The Pediatric Priority Review Voucher (PPRV) program, which expired last year, incentivizes pharmaceutical companies to develop treatments for rare pediatric diseases by offering expedited FDA review vouchers. These vouchers can be used to speed up approvals or sold, generating revenue for further research. Congress can reauthorize this program at no cost to taxpayers, potentially saving countless children's lives.

elmundo.es

🌐 90% Global Worthiness

Feb 5, 07:10

Eleven Blockbuster Drugs to Transform Medicine by 2030

Clarivate's 2025 Drugs to Watch report identifies eleven innovative medicines projected to become blockbusters by 2030, significantly impacting various therapeutic areas, with diabetes/obesity and atopic dermatitis treatments anticipated to lead in revenue generation.

Eleven Blockbuster Drugs to Transform Medicine by 2030

Clarivate's 2025 Drugs to Watch report identifies eleven innovative medicines projected to become blockbusters by 2030, significantly impacting various therapeutic areas, with diabetes/obesity and atopic dermatitis treatments anticipated to lead in revenue generation.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential long-term implications of these new drugs on healthcare systems and patient access?

Future implications include potential shifts in treatment standards across multiple diseases. Cagrisema's success may reshape diabetes/obesity management, while Ebglyss and other new atopic dermatitis therapies could alter treatment strategies. In oncology, innovative mechanisms like PROTAC technology (vepdegestrant) could transform cancer treatment.

cnbc.com

🌐 85% Global Worthiness

Jan 15, 01:07

JPMorgan Health Care Conference: Major Acquisitions and Shifting Market Dynamics

The JPMorgan Health Care Conference in San Francisco saw Johnson & Johnson acquire Intra-Cellular Therapies for \$14.6 billion, exceeding 2024's largest deal; other significant acquisitions were announced by Eli Lilly and GSK, while Moderna and Eli Lilly lowered their 2025 sales guidance. Increased ...

JPMorgan Health Care Conference: Major Acquisitions and Shifting Market Dynamics

The JPMorgan Health Care Conference in San Francisco saw Johnson & Johnson acquire Intra-Cellular Therapies for \$14.6 billion, exceeding 2024's largest deal; other significant acquisitions were announced by Eli Lilly and GSK, while Moderna and Eli Lilly lowered their 2025 sales guidance. Increased ...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the recent killing of a healthcare executive impact the conference, and what broader implications does this event have for the sector's security and public perception?

The conference reflects a robust M&A market in the biotech and pharma sectors, driven by advancements in oncology and other therapeutic areas. The deals suggest optimism towards future growth, particularly under the potential influence of a deal-friendly Trump administration. However, the downward revisions in sales guidance by Moderna and Eli Lilly highlight existing challenges including market competition and fluctuating drug demands.

elmundo.es

🌐 90% Global Worthiness

Jan 8, 16:09

BBVA Award Recognizes GLP-1 Hormone Discoverers for Diabetes, Obesity Treatments

The BBVA Foundation Frontiers of Knowledge Award in Biomedicine was given to four researchers for their discovery of the GLP-1 hormone's role in glucose regulation, appetite, and its implications for treating type 2 diabetes, obesity, and neurodegenerative diseases.

BBVA Award Recognizes GLP-1 Hormone Discoverers for Diabetes, Obesity Treatments

The BBVA Foundation Frontiers of Knowledge Award in Biomedicine was given to four researchers for their discovery of the GLP-1 hormone's role in glucose regulation, appetite, and its implications for treating type 2 diabetes, obesity, and neurodegenerative diseases.

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the research on GLP-1 hormone translate into therapeutic applications, and what are the current and future research directions?

This research, initially focused on the GLP-1 hormone, has expanded to explore its potential in treating neurological diseases like Parkinson's and Alzheimer's, and addiction. The award highlights the translational success of basic science, moving from fundamental biological discoveries to significant therapeutic applications.

english.elpais.com

🌐 90% Global Worthiness

Jan 5, 07:05

Brain-on-a-Chip Improves Alzheimer's Drug Development

The International Iberian Nanotechnology Laboratory (INL) developed a brain-on-a-chip microdevice using microfluidics and a bio-membrane to simulate the blood-brain barrier, enabling more efficient testing of Alzheimer's drugs and reducing reliance on animal testing, potentially accelerating new tre...

Brain-on-a-Chip Improves Alzheimer's Drug Development

The International Iberian Nanotechnology Laboratory (INL) developed a brain-on-a-chip microdevice using microfluidics and a bio-membrane to simulate the blood-brain barrier, enabling more efficient testing of Alzheimer's drugs and reducing reliance on animal testing, potentially accelerating new tre...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What challenges in drug development for neurological disorders does the brain-on-a-chip address, and how does its use of bio-membranes compare to existing methods?

The INL's brain-on-a-chip addresses the challenge of drug delivery across the blood-brain barrier, a major obstacle in developing neurological treatments. Current testing methods, primarily animal models, have limitations due to species differences. This new chip offers a more accurate and ethical alternative by using a bio-membrane that closely mimics the human blood-brain barrier.

cnbc.com

🌐 75% Global Worthiness

Dec 29, 16:07

Biotech Stocks Poised for 2025 Rebound

Biotech stocks are poised for a rebound in 2025, driven by increased merger and acquisition activity, new drug approvals, and a looming patent cliff forcing large pharmaceutical companies to seek innovative biotech partners; however, investors should focus on specific companies rather than broad ind...

Biotech Stocks Poised for 2025 Rebound

Biotech stocks are poised for a rebound in 2025, driven by increased merger and acquisition activity, new drug approvals, and a looming patent cliff forcing large pharmaceutical companies to seek innovative biotech partners; however, investors should focus on specific companies rather than broad ind...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key factors determining which biotech companies will outperform in 2025, and what long-term trends will shape the sector's future?

The biotech sector's future trajectory hinges on several factors: the pace of M&A activity, the success of new drug approvals, and the regulatory environment. Companies with existing market positions and potential for label expansion are viewed favorably. Neurology, immunology, oncology, and metabolic diseases are expected to be attractive areas for Big Pharma acquisitions.

mk.ru

🌐 85% Global Worthiness

Feb 27, 13:14

Progress and Challenges in SMA Treatment in Russia

A February 19th press conference in Moscow discussed Russia's progress in SMA diagnosis and treatment, revealing 1,511 registered patients (1,004 children, 507 adults), over 95% newborn screening coverage in 2023, and the availability of three treatments including a domestic generic.

Progress and Challenges in SMA Treatment in Russia

A February 19th press conference in Moscow discussed Russia's progress in SMA diagnosis and treatment, revealing 1,511 registered patients (1,004 children, 507 adults), over 95% newborn screening coverage in 2023, and the availability of three treatments including a domestic generic.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How are patient advocacy groups and government initiatives contributing to improved SMA care in Russia?

Early diagnosis through expanded newborn screening and the availability of three treatments, including a domestic nusinersen generic, have improved SMA patient outcomes in Russia. Over 700 children are receiving treatment, with 75 using the domestically produced drug. The focus is now on managing patient expectations regarding treatment efficacy and timelines.

cnn.com

🌐 85% Global Worthiness

Jan 31, 04:09

FDA Approves First New Painkiller in Over Two Decades

The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering a safer alternative to opioids; clinical trials showed effectiveness in reducing post-surgical pain, though further research on chronic pain is needed.

FDA Approves First New Painkiller in Over Two Decades

The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering a safer alternative to opioids; clinical trials showed effectiveness in reducing post-surgical pain, though further research on chronic pain is needed.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Journavx's mechanism of action differ from opioids, and what are the implications for addiction and pain relief?

Journavx's mechanism differs from opioids by blocking pain signals before they reach the brain, preventing addiction potential. Clinical trials demonstrated pain reduction comparable to Vicodin for post-surgical pain, although its efficacy for chronic pain like sciatica requires further investigation. The drug's development was inspired by a unique Pakistani family immune to pain.

forbes.com

🌐 85% Global Worthiness

Jan 15, 01:07

ChatGPT Adds Scheduling Feature, Expanding its Personal Assistant Capabilities

OpenAI announced that paying ChatGPT users can now schedule reminders and alerts, showcasing the company's efforts to enhance its conversational AI chatbot with assistant-like capabilities, although it still lags behind competitors in overall functionality.

ChatGPT Adds Scheduling Feature, Expanding its Personal Assistant Capabilities

OpenAI announced that paying ChatGPT users can now schedule reminders and alerts, showcasing the company's efforts to enhance its conversational AI chatbot with assistant-like capabilities, although it still lags behind competitors in overall functionality.

Progress

44% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

How does this new feature position ChatGPT within the broader landscape of AI assistants?

The new ChatGPT feature reflects a broader trend in AI development: integrating assistant-like capabilities into conversational AI models. This is driven by the immense popularity of ChatGPT (over 300 million users) and the market demand for versatile AI assistants.

theguardian.com

🌐 85% Global Worthiness

Jan 8, 10:08

New Alzheimer's Drugs Show Promise but Face Accessibility Barriers

New Alzheimer's drugs, lecanemab and donanemab, slow disease progression by about 30% but are expensive (£20,000-£25,000 annually), require specialized administration and monitoring, and are therefore inaccessible to most of the world's 50 million dementia sufferers, two-thirds of whom live in low- ...

New Alzheimer's Drugs Show Promise but Face Accessibility Barriers

New Alzheimer's drugs, lecanemab and donanemab, slow disease progression by about 30% but are expensive (£20,000-£25,000 annually), require specialized administration and monitoring, and are therefore inaccessible to most of the world's 50 million dementia sufferers, two-thirds of whom live in low- ...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the high costs and complex administration of these new drugs affect access in low- and middle-income countries?

The high cost and complex administration of currently available Alzheimer's drugs highlight inequalities in healthcare access. While these medications represent a significant advancement, their impact is limited by the economic and infrastructural barriers preventing their distribution in many parts of the world, particularly those with limited resources. The need for advanced diagnostic tests like PET scans and intravenous administration further exacerbates these challenges.

jpost.com

🌐 90% Global Worthiness

Jan 3, 01:07

Lenacapavir: A Breakthrough HIV Drug Faces Access Challenges

A new injectable HIV drug, Lenacapavir, demonstrated a 96% reduction in infection risk in clinical trials, leading Science magazine to name it 'Discovery of the Year' for 2024; however, global access is hindered by high costs and limited distribution agreements.

Lenacapavir: A Breakthrough HIV Drug Faces Access Challenges

A new injectable HIV drug, Lenacapavir, demonstrated a 96% reduction in infection risk in clinical trials, leading Science magazine to name it 'Discovery of the Year' for 2024; however, global access is hindered by high costs and limited distribution agreements.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Lenacapavir's high efficacy on HIV prevention efforts, and what specific data support this?

Lenacapavir, a new injectable HIV drug, showed a 96% reduction in infection risk in a clinical trial of 2,179 participants. Only two participants receiving Lenacapavir became infected, compared to nine in the control group using Truvada. This led to Science magazine naming it the 'Discovery of the Year' for 2024.

china.org.cn

🌐 85% Global Worthiness

Dec 14, 16:13

New Antiviral Mechanism Discovered in Bacteria

Chinese scientists discovered CRISPR-CAAD, a new bacterial antiviral mechanism that converts ATP into toxic ITP, hindering phage reproduction and allowing bacteria to resist infection by entering a temporary dormancy state; this finding, published in Science, may lead to new anti-infective drugs.

New Antiviral Mechanism Discovered in Bacteria

Chinese scientists discovered CRISPR-CAAD, a new bacterial antiviral mechanism that converts ATP into toxic ITP, hindering phage reproduction and allowing bacteria to resist infection by entering a temporary dormancy state; this finding, published in Science, may lead to new anti-infective drugs.

Progress

4% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of the newly discovered CRISPR-CAAD antiviral mechanism in bacteria?

Chinese scientists discovered a new antiviral mechanism in bacteria, CRISPR-CAAD, which converts ATP into toxic ITP, hindering phage reproduction. This mechanism allows bacteria to resist phage infection by entering a dormancy-like state and later recovering after eliminating the phages.

Showing 13 to 24 of 27 results